Abstract |
37 patients with disease progression after prior treatment for malignant lymphoma (27 low grade, 7 high grade and 3 Hodgkin's) were treated with oral trofosfamide daily. Most of these patients were heavily pretreated, with a median number of two regimens. Their median performance status was 1 (22 patients with 0-1 and 14 with 2-3). The overall response rate was 49% (18/37; 3/37 CRs and 15/37 (41%) PRs). Median time to progression ( TTP) from start of therapy was 4 months for patients with low-grade lymphoma and 2 months for high-grade lymphoma. For responding patients (CR + PR), TTP was approximately 10 and 7 months, respectively, for the two groups of lymphomas. Median survival from the start of treatment was 11 months (range 1.3-46.6) for low-grade lymphoma and 3.8 months (range 2.2-17.6) for high-grade lymphoma. Haematological and other toxicities were low and did not cause any major treatment interruptions. Trofosfamide is an interesting and a non-toxic palliative treatment for relapsing malignant lymphomas especially in elderly patients.
|
Authors | M D Helsing |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 33
Issue 3
Pg. 500-2
(Mar 1997)
ISSN: 0959-8049 [Print] England |
PMID | 9155539
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Cyclophosphamide
- trofosfamide
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Alkylating
(therapeutic use)
- Cyclophosphamide
(analogs & derivatives, therapeutic use)
- Female
- Hodgkin Disease
(drug therapy)
- Humans
- Lymphoma
(drug therapy)
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Salvage Therapy
|